The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis

被引:5
|
作者
Li, Xiaoyan [1 ]
He, Jie [2 ,3 ]
Sun, Qiuhua [1 ]
机构
[1] Zhejiang Chinese Med Univ, Sch Nursing, 548 Binwen Rd, Hangzhou 310000, Zhejiang, Peoples R China
[2] Chengdu Med Coll, Affiliated Hosp 1, Dept Pulm & Crit Care Med, Chengdu 610500, Sichuan, Peoples R China
[3] Chengdu Med Coll, Clin Med Coll, Chengdu 610500, Sichuan, Peoples R China
关键词
Sarcopenia; Metabolic dysfunction-associated steatotic; liver disease (MASLD); Prevalence; Systematic review; Meta-analysis; INSULIN-RESISTANCE; FIBROSIS; NAFLD; RISK; STEATOHEPATITIS; QUALITY;
D O I
10.1016/j.clnu.2024.07.006
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background and aims: Sarcopenia is a common complication in patients with metabolic dysfunctionassociated steatotic liver disease (MASLD). However, the prevalence and its impact on the survival of sarcopenia in patients with MASLD is unknown. In this study, we aimed to assess the prevalence and effects of sarcopenia in patients with MASLD. Methods: Systematic review and meta-analysis of full texts of relevant studies were searched from inception until June 12, 2024 in five databases (PubMed, Cochrane Library, Embase, Web of Science, and the China National Knowledge Infrastructure). Next, we assessed the prevalence of sarcopenia in MASLD, and calculated the ORs and HRs between sarcopenia and MASLD based on the adjusted data from individual studies. Statistical analyses were performed using Stata 11.0. Results: Of the 2984 records considered, 29 studies recruiting 63,330 patients were included. The pooled prevalence of sarcopenia in patients with MASLD was 23.5% overall (95% CI; 19.1%-27.9%, I2 = 99.6%), and was higher in Asian patients, male, cross-sectional studies, when BIA were employed to measure muscle mass, one criterion of diagnosis sarcopenia, MASLD was diagnosed employing MRI, and moderate-quality studies. Sarcopenia was associated with MASLD patients (adjusted odds ratio [aOR] 2.08, 95% CI 1.58 -2.74, I2 = 93.6%) with similar findings in subgroups stratified by age, study design, methods for measuring muscle mass, assessment method to detect sarcopenia, and study quality. The association between all-cause mortality further supports the association between sarcopenia and poor prognosis with MASLD (aHR 1.59, 95% CI 1.33-1.91, I2 = 0%). Conclusions: Sarcopenia was strongly associated with MASLD progression and was a risk factor not only for MASLD pathogenesis but was also markedly correlated with MASLD-associated mortality. (c) 2024 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:2005 / 2016
页数:12
相关论文
共 50 条
  • [31] Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Elshaer, Amani
    Chascsa, David M. H.
    Lizaola-Mayo, Blanca C.
    LIFE-BASEL, 2024, 14 (07):
  • [32] Quercetin: A Promising Candidate for the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Markowska, Julia
    Kasprzak-Drozd, Kamila
    Nizinski, Przemyslaw
    Dragan, Magdalena
    Kondracka, Adrianna
    Gondek, Ewa
    Oniszczuk, Tomasz
    Oniszczuk, Anna
    MOLECULES, 2024, 29 (22):
  • [33] Metabolic dysfunction-associated steatotic liver disease and atherosclerosis
    Castillo-Nunez, Yulino
    Almeda-Valdes, Paloma
    Gonzalez-Galvez, Guillermo
    Arechavaleta-Granell, Maria del Rosario
    CURRENT DIABETES REPORTS, 2024, 24 (07) : 158 - 166
  • [34] Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies
    Chan, Kai En
    Ong, Elden Yen Hng
    Chung, Charlotte Hui
    Ong, Christen En Ya
    Koh, Benjamin
    Tan, Darren Jun Hao
    Lim, Wen Hui
    Yong, Jie Ning
    Xiao, Jieling
    Wong, Zhen Yu
    Syn, Nicholas
    Kaewdech, Apichat
    Teng, Margaret
    Wang, Jiong-Wei
    Chew, Nicholas
    Young, Dan Yock
    Know, Alfred
    Siddiqui, Mohammad Shadab
    Huang, Daniel Q.
    Tamaki, Nobuharu
    Wong, Vincent Wai-Sun
    Mantzoros, Christos S.
    Sanyal, Arun
    Noureddin, Mazen
    Ng, Cheng Han
    Muthiah, Mark
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 22 (03) : 488 - 498
  • [35] Menopause and metabolic dysfunction-associated steatotic liver disease
    Polyzos, Stergios A.
    Goulis, Dimitrios G.
    MATURITAS, 2024, 186
  • [36] Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma
    Nakamura, Toru
    Masuda, Atsutaka
    Nakano, Dan
    Amano, Keisuke
    Sano, Tomoya
    Nakano, Masahito
    Kawaguchi, Takumi
    CELLS, 2025, 14 (06)
  • [37] Metabolic Dysfunction-Associated Steatotic Liver Disease
    Ali, Sajjadh M. J.
    Lai, Michelle
    ANNALS OF INTERNAL MEDICINE, 2025, 178 (01) : ITC1 - ITC17
  • [38] Intermittent fasting regimens for metabolic dysfunction-associated steatotic liver disease: a systematic review and network meta-analysis of randomized controlled trials
    Abuelazm, Mohamed T.
    Mohamed, Islam
    Naeem, Ahmed
    Khlidj, Yehya
    Tanashat, Mohammad
    Katamesh, Basant E.
    Abusuilik, Husam
    Altobaishat, Obieda
    Abdelnabi, Mohamed
    Abdelazeem, Basel
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2024, 36 (04) : 371 - 381
  • [39] Vitamin E improves serum markers and histology in adults with metabolic dysfunction-associated steatotic liver disease: Systematic review and meta-analysis
    Chee, Nicholas Ming-Zher
    Sinnanaidu, Ram Prasad
    Chan, Wah-Kheong
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 (12) : 2545 - 2554
  • [40] Comment on "Prevalence of and associated factors for sarcopenia in patients with liver cirrhosis: A systematic review and meta-analysis"
    Zhang, Xiao-Ming
    Wang, Wenfei
    Luo, Zaigui
    Fan, Yinping
    Wang, Conghua
    Yang, Yunzhi
    CLINICAL NUTRITION, 2024, 43 (06) : 1665 - 1667